{"key":"survodutide","slug":"survodutide","name":"Survodutide","other_names":[],"kind":"single","area":{"slug":"metabolic","name":"Metabolic"},"classification":"Dual glucagon and GLP-1 receptor agonist","standing":{"id":"phase-3","label":"Phase 3 trials","rank":4},"summary":"A once-weekly peptide that acts on the glucagon and GLP-1 receptors, in phase 3 trials for obesity and studied in fatty liver disease.","cas_number":null,"molecular_formula":null,"molecular_weight":null,"components":[],"has_article":false,"pubmed":{"papers":95,"in_humans":58,"clinical_trials":10},"retired":false,"updated_at":"2026-11-18T00:17:24.691Z","url":"https://pepts.wiki/compounds/survodutide","article":null,"evidence":{"query":"(\"Survodutide\"[tiab])","fetched_at":"2026-11-16T23:07:33.083Z","counts":{"rcts":9,"human":58,"total":95,"reviews":52,"clinicalTrials":10},"years":[{"year":2012,"count":0},{"year":2013,"count":0},{"year":2014,"count":0},{"year":2015,"count":0},{"year":2016,"count":0},{"year":2017,"count":0},{"year":2018,"count":0},{"year":2019,"count":0},{"year":2020,"count":0},{"year":2021,"count":0},{"year":2022,"count":0},{"year":2023,"count":2},{"year":2024,"count":21},{"year":2025,"count":35},{"year":2026,"count":51}],"top":[{"doi":"10.1056/NEJMoa2401755","url":"https://pubmed.ncbi.nlm.nih.gov/38847460/","kind":"rct","pmid":"38847460","year":2024,"title":"A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis","venue":"The New England journal of medicine","authors":"Sanyal AJ, Bedossa P, Fraessdorf M, et al."},{"doi":"10.1097/HEP.0000000000001254","url":"https://pubmed.ncbi.nlm.nih.gov/39903735/","kind":"review","pmid":"39903735","year":2025,"title":"Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis","venue":"Hepatology (Baltimore, Md.)","authors":"Souza M, Al-Sharif L, Antunes VLJ, et al."},{"doi":"10.1016/S2213-8587(23)00356-X","url":"https://pubmed.ncbi.nlm.nih.gov/38330987/","kind":"rct","pmid":"38330987","year":2024,"title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","venue":"The lancet. Diabetes & endocrinology","authors":"le Roux CW, Steen O, Lucas KJ, et al."},{"doi":"10.1124/pharmrev.123.001045","url":"https://pubmed.ncbi.nlm.nih.gov/39952695/","kind":"review","pmid":"39952695","year":2025,"title":"Emerging pharmacotherapies for obesity: A systematic review","venue":"Pharmacological reviews","authors":"Kokkorakis M, Chakhtoura M, Rhayem C, et al."},{"doi":"10.1002/oby.24360","url":"https://pubmed.ncbi.nlm.nih.gov/40685589/","kind":"review","pmid":"40685589","year":2025,"title":"Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA","venue":"Obesity (Silver Spring, Md.)","authors":"Sinha B, Ghosal S"},{"doi":"10.1056/NEJMoa2600751","url":"https://pubmed.ncbi.nlm.nih.gov/42253238/","kind":"rct","pmid":"42253238","year":2026,"title":"Survodutide Once Weekly for the Treatment of Adults with Obesity","venue":"The New England journal of medicine","authors":"le Roux CW, Wharton S, Startseva E, et al."},{"doi":"10.2337/dci24-0003","url":"https://pubmed.ncbi.nlm.nih.gov/38843460/","kind":"review","pmid":"38843460","year":2024,"title":"Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity","venue":"Diabetes care","authors":"Drucker DJ"}]},"library_version":"183:2026-11-17T11:05:42.386Z","attribution":"Data from Pepts.wiki (https://pepts.wiki), CC BY 4.0. Link back to the compound's page.","notice":"We are not doctors, and nothing on Pepts.wiki is medical advice or a recommendation to use anything. The wiki sets out what studies measured, as clearly and evenly as it can, so you can make better-informed decisions. Always consult a medical professional before acting on anything you read here."}